US5521184A
(en)
*
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
GB9212673D0
(en)
*
|
1992-06-15 |
1992-07-29 |
Celltech Ltd |
Chemical compounds
|
US6171786B1
(en)
|
1992-09-17 |
2001-01-09 |
Board Of Trustees Of University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
US5972598A
(en)
*
|
1992-09-17 |
1999-10-26 |
Board Of Trustess Of The University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
ES2262137T3
(en)
*
|
1993-10-01 |
2006-11-16 |
Novartis Ag |
PHARMACOLOGICALLY ACTIVE PIRIMIDINAMINE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION.
|
US5612340A
(en)
*
|
1993-10-01 |
1997-03-18 |
Ciba-Geigy Corporation |
Pyrimidineamine derivatives and processes for the preparation thereof
|
RU2135491C1
(en)
*
|
1993-10-01 |
1999-08-27 |
Новартис Аг |
Derivatives of n-phenyl-2-pyrimidineamine, method of their synthesis, pharmaceutical composition on said and method of inhibition (treatment) of tumor
|
US5543520A
(en)
*
|
1993-10-01 |
1996-08-06 |
Ciba-Geigy Corporation |
Pyrimidine derivatives
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
DE69433594T2
(en)
*
|
1993-12-22 |
2004-08-05 |
Celltech R&D Ltd., Slough |
TRISUBSTITUTED PHENYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS PHOSPHODIESTERASE (TYPE IV) INHIBITORS
|
GB9326699D0
(en)
*
|
1993-12-22 |
1994-03-02 |
Celltech Ltd |
Chemical compounds
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
GB9412571D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412573D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412672D0
(en)
*
|
1994-06-23 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
US5756527A
(en)
*
|
1995-06-07 |
1998-05-26 |
Ontogen Corporation |
Imidazole derivatives useful as modulators of multi drug resistances
|
GB9523675D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0812829A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Substituted imidazoles as modulators of multi-drug resistance
|
EP0812830A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Modulators of multi-drug resistances
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
WO1998028281A1
(en)
|
1996-12-23 |
1998-07-02 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
*
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CO4940418A1
(en)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
WO2001000214A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
US6498165B1
(en)
|
1999-06-30 |
2002-12-24 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
US6329380B1
(en)
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
EA200200351A1
(en)
|
1999-09-10 |
2002-10-31 |
Мерк Энд Ко., Инк. |
Thyrosine Kinase Inhibitors
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CN1429222A
(en)
*
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
Kinase inhibitors
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7087608B2
(en)
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
EP1964839A3
(en)
|
2000-08-18 |
2008-11-05 |
Millennium Pharmaceuticals, Inc. |
Quinazoline derivatives as kinase inhibitors
|
GB0022438D0
(en)
*
|
2000-09-13 |
2000-11-01 |
Novartis Ag |
Organic Compounds
|
WO2002034727A2
(en)
*
|
2000-10-27 |
2002-05-02 |
Novartis Ag |
Treatment of gastrointestinal stromal tumors
|
ATE502928T1
(en)
|
2000-11-01 |
2011-04-15 |
Millennium Pharm Inc |
NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
DK3143995T3
(en)
|
2001-02-19 |
2019-01-28 |
Novartis Pharma Ag |
Rapamycin derivative for the treatment of lung cancer
|
SE0100569D0
(en)
*
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
BR0207649A
(en)
*
|
2001-02-27 |
2004-03-09 |
Novartis Ag |
A combination comprising a signal transduction inhibitor and an epothilone derivative
|
EP2253319A1
(en)
|
2001-05-16 |
2010-11-24 |
Novartis AG |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
|
WO2002093164A2
(en)
*
|
2001-05-16 |
2002-11-21 |
Axxima Pharmaceuticals Ag |
Pyridylpyrimidine derivatives as effective compounds against prion diseases
|
EP2322628B1
(en)
|
2001-06-14 |
2017-03-15 |
The Regents of The University of California |
Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
|
WO2003000186A2
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel phenylamino-pyrimidines and uses thereof
|
AU2002346053B2
(en)
|
2001-06-22 |
2008-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
EP1434991B1
(en)
*
|
2001-06-29 |
2007-10-17 |
AB Science |
New potent, selective and non toxic c-kit inhibitors
|
DK1401416T5
(en)
|
2001-06-29 |
2007-03-19 |
Ab Science |
Use of C-kit inhibitors for the treatment of inflammatory bowel disease
|
JP2004537536A
(en)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
Methods of using tyrosine kinase inhibitors to treat allergic diseases
|
JP2004530730A
(en)
*
|
2001-06-29 |
2004-10-07 |
アブ サイエンス |
Use of a potent, selective and non-toxic c-kit inhibitor for treating tumor angiogenesis
|
PT1401415E
(en)
|
2001-06-29 |
2006-09-29 |
Ab Science |
USING N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
|
EP1427422A1
(en)
*
|
2001-09-20 |
2004-06-16 |
AB Science |
Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
|
WO2003040141A1
(en)
*
|
2001-09-28 |
2003-05-15 |
Bayer Pharmaceuticals Corporation |
Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
|
EP2343366A1
(en)
|
2001-10-05 |
2011-07-13 |
Novartis AG |
Mutated Abl kinase domains
|
GB0201508D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
GB0202874D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
GB0202873D0
(en)
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
AU2007203463B2
(en)
*
|
2002-02-07 |
2010-12-23 |
Novartis Pharma Ag |
N-phenyl-2-pyrimidine-amine derivatives
|
WO2003070248A1
(en)
*
|
2002-02-22 |
2003-08-28 |
The Government Of The United States The Department Of Veterans Affairs |
Use of 4-(4-methylpiperazin-1-ylmethyl)-n[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]-benzamide for treating seminomas
|
US20050203098A1
(en)
*
|
2002-02-27 |
2005-09-15 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating substance use disorders
|
CA2477111A1
(en)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
CN1326577C
(en)
*
|
2002-02-28 |
2007-07-18 |
诺瓦提斯公司 |
N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
AU2003249369A1
(en)
|
2002-06-21 |
2004-01-06 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
US20060052387A1
(en)
*
|
2002-06-26 |
2006-03-09 |
Marsh Clay B |
Organic compounds
|
ES2337995T3
(en)
*
|
2002-06-28 |
2010-05-03 |
Nippon Shinyaku Co., Ltd. |
DERIVATIVE OF AMIDA.
|
GB0215676D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
DK1525200T3
(en)
*
|
2002-08-02 |
2007-12-03 |
Ab Science |
2- (3-aminoaryl) amino-4-aryl-thiazoles for disease treatment
|
GB0222514D0
(en)
*
|
2002-09-27 |
2002-11-06 |
Novartis Ag |
Organic compounds
|
AU2003273986A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Novartis Ag |
Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
GB2398565A
(en)
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
KR20060002933A
(en)
*
|
2003-04-04 |
2006-01-09 |
베이코 테크 리미티드 |
Vascular stent
|
WO2004099186A1
(en)
|
2003-05-06 |
2004-11-18 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
BRPI0410439A
(en)
|
2003-05-19 |
2006-06-06 |
Irm Llc |
immunosuppressive compounds and compositions
|
RU2365373C2
(en)
*
|
2003-05-27 |
2009-08-27 |
Роберт Пер Хэгерквист |
Use of tyrosine kinase inhibitor for diabetes treatment
|
PT1635835E
(en)
*
|
2003-06-13 |
2010-03-17 |
Novartis Ag |
2-aminopyrimidine derivatives as raf kinase inhibitors
|
PT1660057E
(en)
|
2003-08-27 |
2012-08-02 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
ATE428426T1
(en)
|
2003-11-18 |
2009-05-15 |
Novartis Pharma Gmbh |
INHIBITOR OF THE MUTANT FORM OF KIT
|
WO2005063709A1
(en)
|
2003-12-25 |
2005-07-14 |
Nippon Shinyaku Co., Ltd. |
Amide derivative and medicine
|
WO2005072826A2
(en)
*
|
2004-01-21 |
2005-08-11 |
Emory University |
Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
|
AR047530A1
(en)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
FORMS OF SALT OF 4- (4-METHYLIPIPERAZIN-1-ILMETIL) -N- (4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL) -BENZAMIDA
|
PL1720853T3
(en)
|
2004-02-11 |
2016-06-30 |
Natco Pharma Ltd |
Novel polymorphic form of imatinib mesylate and a process for its preparation
|
CN1309719C
(en)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
Derivative of phenylamide pyrimidine and application thereof
|
PE20110102A1
(en)
|
2004-04-07 |
2011-02-07 |
Novartis Ag |
DERIVATIVES OF N- (2-OXO-2-PYRROLIDINYL-1-IL) ETHYL-2-AMINO-ACETAMIDE AS INHIBITORS OF APOPTOSIS PROTEINS (IAP)
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
CA2578122A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Gpc Biotech Ag |
Pyrimidine derivatives
|
US8269003B2
(en)
|
2004-09-02 |
2012-09-18 |
Cipla Limited |
Stable crystal form of imatinib mesylate and process for the preparation thereof
|
US7939541B2
(en)
*
|
2004-09-09 |
2011-05-10 |
Natco Pharma Limited |
Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
WO2006027795A1
(en)
|
2004-09-09 |
2006-03-16 |
Natco Pharma Limited |
Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
PL1833815T3
(en)
*
|
2004-12-30 |
2011-03-31 |
Inst Farmaceutyczny |
A process for preparation of imatinib base
|
CN1939910A
(en)
*
|
2004-12-31 |
2007-04-04 |
孙飘扬 |
Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
|
CN1972917B
(en)
*
|
2004-12-31 |
2010-08-25 |
孙飘扬 |
Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
|
BRPI0606480A
(en)
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
pharmaceutical compounds
|
MX2007013741A
(en)
|
2005-05-02 |
2008-01-21 |
Novartis Ag |
Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis.
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
UA96139C2
(en)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Anti-neuropilin-1 (nrp1) antibody
|
EP2022498A3
(en)
|
2005-11-21 |
2012-08-15 |
Novartis AG |
Neuroendocrine tumour treatment
|
KR20130140909A
(en)
|
2005-11-25 |
2013-12-24 |
노파르티스 아게 |
F, g, h, i and k crystal forms of imatinib mesylate
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
CN101415409B
(en)
|
2006-04-05 |
2012-12-05 |
诺瓦提斯公司 |
Combinations of therapeutic agents for treating cancer
|
MX2008012728A
(en)
|
2006-04-05 |
2008-10-14 |
Novartis Ag |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer.
|
PE20080251A1
(en)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
USES OF DPP IV INHIBITORS
|
US20090317489A1
(en)
|
2006-05-09 |
2009-12-24 |
Hanspeter Nick |
Combination Comprising an Iron Chelator and an Anti-Neoplastic Agent and Use Thereof
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
WO2007138705A1
(en)
|
2006-06-01 |
2007-12-06 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
Tumor suppressor
|
EP2081933B1
(en)
|
2006-09-29 |
2011-03-23 |
Novartis AG |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP1966186A1
(en)
*
|
2006-10-26 |
2008-09-10 |
Sicor Inc. |
Process for the preparation of imatinib
|
RU2480461C2
(en)
*
|
2006-11-16 |
2013-04-27 |
Ф.И.С. Фаббрика Итальяна Синтетичи С.П.А. |
Method of producing imatinib and intermediate compounds thereof
|
CN101245061B
(en)
*
|
2007-02-13 |
2012-09-19 |
天津天士力集团有限公司 |
N-(5-amido-2-methyl phenyl)-4-(3-pyridinyl)-2-aminopyrimidine nitric oxide donating derivant, production method and uses thereof
|
JP2010519209A
(en)
|
2007-02-15 |
2010-06-03 |
ノバルティス アーゲー |
Combination of LBH589 and other therapeutic agents for treating cancer
|
RU2329260C1
(en)
*
|
2007-02-20 |
2008-07-20 |
Юрий Иосифович Копырин |
Method of obtaining 2-anilinopyrimidines or their salts (options)
|
KR20090128396A
(en)
*
|
2007-03-12 |
2009-12-15 |
닥터 레디스 레보러터리즈 리미티드 |
Imatinib mesylate
|
WO2008117298A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Natco Pharma Limited |
A novel method of preparation of imatinib
|
US7550591B2
(en)
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
WO2008153974A1
(en)
|
2007-06-07 |
2008-12-18 |
Intra-Cellular Therapies, Inc. |
Novel heterocycle compounds and uses thereof
|
JP5710251B2
(en)
|
2007-06-07 |
2015-04-30 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
Novel heterocyclic compounds and uses thereof
|
JP5611826B2
(en)
*
|
2007-09-04 |
2014-10-22 |
ザ スクリプス リサーチ インスティテュート |
Substituted pyrimidinyl-amines as protein kinase inhibitors
|
WO2009060463A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Natco Pharma Limited |
An environmentally friendly process for the preparation of imatinib base
|
EP2062885A1
(en)
*
|
2007-11-21 |
2009-05-27 |
Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. |
Acid addition salts of imatinib and formulations comprising the same
|
SI2252597T1
(en)
*
|
2008-02-01 |
2014-07-31 |
Akinion Pharmaceuticals Ab |
Pyrazine derivatives and their use as protein kinase inhibitors
|
WO2009118292A1
(en)
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
MX2010010502A
(en)
|
2008-03-26 |
2010-10-26 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b.
|
CN101584696A
(en)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
Composition containing quinazoline derivatives, preparation method and use
|
EA029131B1
(en)
|
2008-05-21 |
2018-02-28 |
Ариад Фармасьютикалз, Инк. |
Phosphorous derivatives as kinase inhibitors
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
PL215042B1
(en)
*
|
2008-08-01 |
2013-10-31 |
Temapharm Spolka Z Ograniczona Odpowiedzialnoscia |
Method of imatinib manufacturing
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
MX2011001525A
(en)
|
2008-08-15 |
2011-03-29 |
Boehringer Ingelheim Int |
Purin derivatives for use in the treatment of fab-related diseases.
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
ES2704986T3
(en)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
|
EP2186514B1
(en)
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
JP2012512885A
(en)
|
2008-12-18 |
2012-06-07 |
ノバルティス アーゲー |
New salt
|
ES2531831T3
(en)
|
2008-12-18 |
2015-03-20 |
Novartis Ag |
Polymorphic form of 1- (4- {1 - [(E) -4-cyclohexyl-3-trifluoromethyl-benzyloxyimino] -ethyl} -2-ethyl-benzyl) -azetidine-3-carboxylic acid
|
CN104803902A
(en)
|
2008-12-18 |
2015-07-29 |
诺华股份有限公司 |
Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -azetidine-3-carboxylic acid
|
MX2011006713A
(en)
|
2008-12-23 |
2011-07-13 |
Boehringer Ingelheim Int |
Salt forms of organic compound.
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
EP2391366B1
(en)
|
2009-01-29 |
2012-11-28 |
Novartis AG |
Substituted benzimidazoles for the treatment of astrocytomas
|
AR075204A1
(en)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2
|
CN102387795A
(en)
|
2009-02-13 |
2012-03-21 |
贝林格尔.英格海姆国际有限公司 |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
TW201102068A
(en)
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
DK2445903T3
(en)
|
2009-06-26 |
2014-06-23 |
Novartis Ag |
1,3-Disubstituted imidazolidin-2-one derivatives as CYP17 inhibitors
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
WO2011018454A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
MX2012002066A
(en)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Heterocyclic compounds and uses thereof.
|
AU2010284972A1
(en)
|
2009-08-20 |
2012-03-08 |
Novartis Ag |
Heterocyclic oxime compounds
|
KR20120050492A
(en)
|
2009-08-26 |
2012-05-18 |
노파르티스 아게 |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
WO2011029915A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
BR112012007234A2
(en)
|
2009-10-02 |
2016-04-05 |
Boehringer Ingelheim Int |
pharmaceutical combination comprising dpp-4 inhibitor and metformin, as well as their use and preparation process
|
AU2010303780B2
(en)
|
2009-10-09 |
2014-02-20 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
PL389357A1
(en)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Tartaric acids derivatives imatinib salts and process for the preparation thereof
|
PE20121471A1
(en)
|
2009-11-04 |
2012-11-01 |
Novartis Ag |
HELPFUL HETEROCYCLIC SULFONAMIDE DERIVATIVES AS MEK INHIBITORS
|
AU2010321533A1
(en)
|
2009-11-23 |
2012-05-31 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
EP2504339A1
(en)
|
2009-11-25 |
2012-10-03 |
Novartis AG |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
KR20230021159A
(en)
|
2009-11-27 |
2023-02-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
JP5456908B2
(en)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
Heterocyclic sulfonamide derivatives
|
WO2011070588A1
(en)
|
2009-12-10 |
2011-06-16 |
Arch Pharmalabs Limited |
Process for the preparation of imatinib and salts thereof
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
CA2789989A1
(en)
|
2010-02-15 |
2011-08-18 |
Reliance Life Sciences Pvt. Ltd. |
Process for the preparation of alpha form of imatinib mesylate
|
PL390611A1
(en)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Process for the preparation of polymorphic alpha form and new polymorphic form of imatinib mesylate
|
US20130060030A1
(en)
|
2010-03-15 |
2013-03-07 |
Natco Pharma Limited |
Process for the preparation of highly pure crystalline imatinib base
|
JP2013522279A
(en)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Combination of GPR119 agonist and DDP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
WO2011130918A1
(en)
*
|
2010-04-23 |
2011-10-27 |
上海百灵医药科技有限公司 |
Process for synthesizing imatinib
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
CN102946875A
(en)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
Combination therapy
|
CN102947274A
(en)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EP2582681A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
SI2582689T1
(en)
|
2010-06-18 |
2017-05-31 |
Krka, D.D., Novo Mesto |
New polymorphic form of imatinib base and preparation of salts thereof
|
PL234542B1
(en)
|
2010-06-21 |
2020-03-31 |
Zakl Farmaceutyczne Polpharma Spolka Akcyjna |
Pharmaceutical compositions comprising imatinib or a pharmaceutically acceptable salt thereof and methods for their preparation
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
BR112013000340A2
(en)
|
2010-07-09 |
2016-05-31 |
Genentech Inc |
isolated antibody that binds neuropillin-1 (nrp1), isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate and method of detecting nrp1 in a biological sample
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
RU2013110058A
(en)
|
2010-08-11 |
2014-09-20 |
Синтон Б.В. |
PHARMACEUTICAL GRANULATE CONTAINING IMATINIB MESILATE
|
TR201007005A2
(en)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
Imatinib base production method
|
JP2013537210A
(en)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
17α-hydroxylase / C17,20-lyase inhibitor
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TR201010618A2
(en)
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
An oral dosage form comprising imatinib and the manufacture of an oral dosage form
|
WO2012085815A1
(en)
|
2010-12-21 |
2012-06-28 |
Novartis Ag |
Bi-heteroaryl compounds as vps34 inhibitors
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
JP2014505088A
(en)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
[1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
|
AR085397A1
(en)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
COMBINATION OF QUINASA INHIBITORS AND THEIR USES
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CZ305457B6
(en)
|
2011-02-28 |
2015-09-30 |
Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. |
Pyrimidine compounds inhibiting formation of nitrogen monoxide and prostaglandin E2, process for their preparation and use
|
WO2012120469A1
(en)
|
2011-03-08 |
2012-09-13 |
Novartis Ag |
Fluorophenyl bicyclic heteroaryl compounds
|
PL394169A1
(en)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
|
EP2508525A1
(en)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
JP6002210B2
(en)
|
2011-04-28 |
2016-10-05 |
ノバルティス アーゲー |
17α-hydroxylase / C17,20-lyase inhibitor
|
US9834518B2
(en)
|
2011-05-04 |
2017-12-05 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
CN102796110B
(en)
*
|
2011-05-23 |
2016-03-30 |
复旦大学 |
Aniline pyrimidine compound and its production and use
|
EP2718276A1
(en)
|
2011-06-09 |
2014-04-16 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
KR20140025530A
(en)
|
2011-06-27 |
2014-03-04 |
노파르티스 아게 |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
ITMI20111309A1
(en)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
PREPARATION PROCEDURE OF IMATINIB MESILATO
|
HUE043540T2
(en)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
WO2013035102A1
(en)
|
2011-09-05 |
2013-03-14 |
Natco Pharma Limited |
Processes for the preparation of imatinib base and intermediates thereof
|
ES2691650T3
(en)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met
|
EP2776035B1
(en)
|
2011-11-01 |
2016-08-10 |
Modgene, Llc |
Compositions and methods for reduction of amyloid-beta load
|
RU2486180C1
(en)
*
|
2011-11-02 |
2013-06-27 |
Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") |
Method for preparing 2-arylamino-4-hetarylpyrimidines
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103159739A
(en)
*
|
2011-12-09 |
2013-06-19 |
天津市国际生物医药联合研究院有限公司 |
1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof
|
AP4055A
(en)
|
2011-12-22 |
2017-03-07 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
CA2859867A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140107574A
(en)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140107573A
(en)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
MX2014007725A
(en)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners.
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
PL226174B1
(en)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Combination therapy of non-small-cell lung carcinoma
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
WO2013120852A1
(en)
|
2012-02-13 |
2013-08-22 |
Grindeks, A Joint Stock Company |
Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
|
IN2012DE00728A
(en)
|
2012-03-13 |
2015-08-21 |
Fresenius Kabi Oncology Ltd |
|
EP3964513A1
(en)
|
2012-04-03 |
2022-03-09 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2013161851A1
(en)
|
2012-04-24 |
2013-10-31 |
中外製薬株式会社 |
Benzamide derivative
|
JP6130828B2
(en)
|
2012-04-24 |
2017-05-17 |
中外製薬株式会社 |
Quinazolinedione derivatives
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
ES2929025T3
(en)
|
2012-05-14 |
2022-11-24 |
Boehringer Ingelheim Int |
Linagliptin, a xanthine derivative as a dpp-4 inhibitor, for use in the treatment of SIRS and/or sepsis
|
JP6224084B2
(en)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
|
WO2013174768A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2855483B1
(en)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinone compounds
|
BR112014031421A2
(en)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
cancer treatment compositions and methods for producing them
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
EP2879675B1
(en)
|
2012-08-06 |
2019-11-13 |
Duke University |
Compounds and methods for targeting hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
CN103664787B
(en)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
Alkynes heteroaromatic ring compounds and application thereof
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
WO2014048377A1
(en)
|
2012-09-28 |
2014-04-03 |
杭州本生药业有限公司 |
Drug composition for treating tumors and application thereof
|
US9487500B2
(en)
*
|
2012-10-04 |
2016-11-08 |
Inhibikase Therapeutics, Inc. |
Compounds and compositions thereof
|
CN110787285A
(en)
|
2012-11-05 |
2020-02-14 |
达纳-法伯癌症研究所股份有限公司 |
XBP1, CD138, and CS1 peptides, pharmaceutical compositions including the peptides, and methods of using the peptides and compositions
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
CN103848812B
(en)
*
|
2012-12-04 |
2016-08-03 |
北大方正集团有限公司 |
The method of refined imatinib
|
CN103044394A
(en)
*
|
2012-12-20 |
2013-04-17 |
北京理工大学 |
Phenyl aminopyrimidine derivant and preparation method and application thereof
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014124860A1
(en)
|
2013-02-14 |
2014-08-21 |
Boehringer Ingelheim International Gmbh |
Specific pde4b-inhibitors for the treatment of diabetes mellitus
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
BR112015019603A2
(en)
|
2013-02-20 |
2017-08-22 |
Novartis Ag |
ISOLATED NUCLEIC ACID MOLECULES, ISOLATED POLYPEPTIDE MOLECULES, ISOLATED CAR MOLECULES, ANTI-EGFRVIII BINDING DOMAIN, VECTOR, CELL AND USE OF AN EFFECTIVE AMOUNT THEREOF, AND METHODS FOR PRODUCING A CELL AND PRODUCING A POPULATION OF CELLS MODIFIED BY RNA
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
EP2803353B1
(en)
|
2013-05-14 |
2018-05-23 |
Hetero Research Foundation |
Compositions of Imatinib
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
EP3046921A4
(en)
|
2013-09-22 |
2017-02-22 |
Calitor Sciences, LLC |
Substituted aminopyrimidine compounds and methods of use
|
US9901579B2
(en)
|
2013-10-17 |
2018-02-27 |
Sartar Therapeutics Ltd |
Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
|
EP3061749B1
(en)
|
2013-10-23 |
2019-02-27 |
Chugai Seiyaku Kabushiki Kaisha |
Quinazolinone and isoquinolinone derivative
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
WO2015148869A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
US10426753B2
(en)
|
2014-04-03 |
2019-10-01 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
EP2927223B1
(en)
|
2014-04-04 |
2016-06-29 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Process for preparing imatinib and salts thereof, free of genotoxic impurity f
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
EP3174869B1
(en)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Combination therapy of a met inhibitor and an egfr inhibitor
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
CN105585556A
(en)
*
|
2014-11-13 |
2016-05-18 |
连云港杰瑞药业有限公司 |
Synthetic method of imatinib
|
JP2018527362A
(en)
|
2015-09-11 |
2018-09-20 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
Substituted heteroaryl compounds and methods of use
|
EP3407874A1
(en)
|
2016-01-25 |
2018-12-05 |
KRKA, d.d., Novo mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
MX2018011349A
(en)
|
2016-03-25 |
2019-02-07 |
Ab Science |
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation.
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
CN109310697A
(en)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
The combination of Li Gelieting and melbine
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
CN107652269A
(en)
*
|
2016-07-26 |
2018-02-02 |
江苏豪森药业集团有限公司 |
Methanesulfonic acid fluorine imatinib purification of intermediate method
|
EP3503914A1
(en)
|
2016-08-23 |
2019-07-03 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
CN107805240A
(en)
*
|
2016-09-08 |
2018-03-16 |
中国科学院合肥物质科学研究院 |
A kind of new PDGFR kinase inhibitors and application thereof
|
KR20190054094A
(en)
|
2016-09-27 |
2019-05-21 |
세로 테라퓨틱스, 인코포레이티드 |
Chimeric phagocytic receptor molecule
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
EP3333162A1
(en)
|
2016-12-12 |
2018-06-13 |
Silesian Catalysts sp. z o.o. |
Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
|
CN107089969B
(en)
*
|
2017-04-26 |
2020-04-24 |
黑龙江鑫创生物科技开发有限公司 |
Method for synthesizing imatinib intermediate
|
WO2019067328A1
(en)
|
2017-09-26 |
2019-04-04 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
WO2019083962A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and hdac inhibitors for treating multiple myeloma
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
JP7021356B2
(en)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
Pyrimidine derivative kinase inhibitors
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
CA3093973A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
EP3774869A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
KR20210032468A
(en)
|
2018-07-17 |
2021-03-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
Heart-safe antidiabetic therapy
|
EP3823625A1
(en)
|
2018-07-17 |
2021-05-26 |
Boehringer Ingelheim International GmbH |
Cardio- and renosafe antidiabetic therapy
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
Compounds, derivatives, and analogs for cancer
|
WO2021009686A1
(en)
|
2019-07-15 |
2021-01-21 |
Intas Pharmaceuticals Ltd. |
Pharmaceutical composition of imatinib
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
CN117203223A
(en)
|
2021-02-26 |
2023-12-08 |
凯洛尼亚疗法有限公司 |
Lymphocyte targeting lentiviral vectors
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|